Mission and Business Strategy:
The principal activity of CeNeRx is the development and commercialization of a
balanced portfolio of precedented, semi-precedented & novel drugs for the
treatment of central nervous system disorders from early to mid stage development
(pre-clinical to phase III ready).
Immediate Focus:
CeNeRx will focus initially on rapidly advancing its current antidepressant series
which work as reversible inhibitors of monoamine oxidase-A (RIMA). CeNeRx looks to
expand its portfolio through licensing of complementary products and programs.
